Compare Amphastar Pharmaceuticals Inc (AMPH) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Msci Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.53 (market cap $826.08M), while Msci Inc trades at $617.48 (market cap $44.02B). The key difference: Msci Inc is far larger — about 53.3× Amphastar Pharmaceuticals Inc's market cap, and Msci Inc pays a 1.36% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MSCI | |
|---|---|---|
Market Cap | $826.08M | $44.02B |
Sector | Health | Financials |
52-Week High | $30.81 | $643.83 |
52-Week Low | $16.87 | $511.84 |
Enterprise Value | $1.22B | $50.19B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
MSCI trades at $604.71, up 0.23% today, with a bullish technical signal and strong support at $595. The stock shows robust fundamentals with revenue growth to $3.13B in 2025 and a net income margin of 40.74%, though valuations are elevated with a P/E of 34.54. Recent news highlights strategic partnerships with UBS and acquisitions to enhance its private markets and climate risk capabilities.
Outlook is positive given consistent earnings beats and a consensus price target of $718.14, but risks include high debt levels and reliance on market data demand. Analyst sentiment is strongly bullish with 73% buy ratings, supporting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
